Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.

In Q3 FY2025, it reported $35.1 billion in revenue. up 94% year-over-year, with data center revenue up 112% to $30.8 billion. Non-GAAP EPS reached $0.81 and grew 103% year-over-year. These results ...

Amazon (AMZN) stock is pulling back, after a better-than-expected fourth quarter was overshadowed by a weak forecast ...

Because of its cryptocurrency hoarding strategy, MicroStrategy (NASDAQ:MSTR) is now a big deal. It needs a new name to go along with its plus-sized game plan, so it has rebranded as Strategy. It is ...

We recently compiled a list of the Why These 15 Bank Stocks Are Skyrocketing So Far In 2025. In this article, we are going to ...

We recently compiled a list of the Why These 15 Bank Stocks Are Skyrocketing So Far In 2025. In this article, we are going to ...

Iterum Therapeutics PLC (NASDAQ:ITRM) reported its fourth-quarter 2024 financial results, revealing a narrower-than-expected loss. The company posted an actual EPS of -0.12, beating the forecasted EPS ...

We recently compiled a list of the Why These 15 Bank Stocks Are Skyrocketing So Far In 2025. In this article, we are going to ...

We recently compiled a list of the Why These 15 Bank Stocks Are Skyrocketing So Far In 2025. In this article, we are going to ...

We recently compiled a list of the Why These 15 Bank Stocks Are Skyrocketing So Far In 2025. In this article, we are going to ...

Varonis Systems (NASDAQ:VRNS) reported its financial results for the fourth quarter of 2024, showcasing a modest revenue increase of 3% year-over-year to $158.5 million. Despite surpassing earnings ...

SouthernSun Asset Management, LLC, an investment management firm, released its “SouthernSun Small Cap Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The ...